A-769662 是一种 AMP 活化蛋白激酶 (AMPK) 激活剂,它通过 AMPK 非依赖机制抑制 26S 蛋白酶体的功能从而导致细胞周期停滞,可直接刺激部分纯化的大鼠肝脏 AMPK (EC50 = 0.8 μM),并抑制原代大鼠肝细胞中的脂肪酸合成 (IC50 = 3.2 μM),还可缓解 2 型糖尿病等代谢性疾病的症状。
产品编号: MS-O37495 纯度: 99.33% CAS No.: 844499-71-4 分子式: C20H12N2O3S 分子量: 360.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

A-769662 是一种 AMP 活化蛋白激酶 (AMPK) 激活剂,它通过 AMPK 非依赖机制抑制 26S 蛋白酶体的功能从而导致细胞周期停滞,可直接刺激部分纯化的大鼠肝脏 AMPK (EC50 = 0.8 μM),并抑制原代大鼠肝细胞中的脂肪酸合成 (IC50 = 3.2 μM),还可缓解 2 型糖尿病等代谢性疾病的症状。

生物实验数据

生物活性 A-769662 is an AMP-activated protein kinase (AMPK) activator that inhibits the function of the 26S proteasome through an AMPK-independent mechanism, leading to cell cycle arrest, directly stimulates partially purified rat liver AMPK (EC50 = 0.8 μM), inhibits fatty acid synthesis in primary rat hepatocytes (IC50 = 3.2 μM), and alleviates symptoms of metabolic diseases such as type 2 diabetes.
IC50 & Target AMPK:0.8 μM (EC50)
体外研究
(In Vitro)

A-769662 (0.1-100 μM) increases AMPK activity in the presence of a saturating concentration of AMP (300 μM).
A-769662 (1 nM-1 mM, 4h) increases acetyl-CoA carboxylase (ACC) phosphorylation dose-dependently in primary rat hepatocytes.
A-769662 (50-300 μM, 1 h) increases the GFP-dependent fluorescence dose-dependently in HEK-GFPu-1 cells.
A-769662 (0-50 μM, 1 h) is able to reduce the activity of pre-existing proteasomal activity in MEF cells.

Western Blot Analysis

Cell Line: Primary rat hepatocytes
Concentration: Primary rat hepatocytes
Incubation Time: 4 h
Result: Increased ACC phosphorylation dose-dependently.
Showed that increased ACC phosphorylation correlated with inhibition of fatty acid synthesis as measured by incorporation of 14C-acetate into fatty acids with IC50 of 3.2 μM.
体内研究
(In Vivo)

A-769662 (30 mg/kg,腹腔注射,单剂量) 显著降低了相对于载体的呼吸交换率,表明尽管 Sprague Dawley 大鼠体内有碳水化合物,但脂肪酸利用率仍增加。
A-769662 (3-30 mg/kg,腹腔注射,每日两次,共 5 天) 降低了肥胖/肥胖小鼠和瘦型同窝小鼠的血糖水平、脂质和 ACC 活性。
A-769662 (3-30 mg/kg,腹腔注射,每日两次,共 14 天) 降低了肥胖/肥胖小鼠和瘦型同窝小鼠的血糖水平。
A-769662 (10-300 μM,1 小时) 抑制在小鼠胚胎成纤维细胞 (MEF) 中,蛋白酶体功能显著增强,在野生型和双 α1 -/- α1 -/- KO 小鼠中的 IC50 为 62 μM。
A-769662 (300 μM) 对野生型和双 α1 -/- α1 -/- KO 小鼠的 MEF 细胞有毒性作用。
A-769662 (15-30 mg/kg,腹腔注射,2 周) 可诱导 AMPK 活化,从而使糖尿病小鼠的神经功能变化正常化,并减轻与糖尿病神经病变 (DN) 相关的疼痛。

Animal Model: Sprague Dawley rats fed ad libitum prior were first acclimated by placing them in a gas exchange indirect calorimeter without food for 2 h then gavaged with a mixed meal plus A-769662
Dosage: 30 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Resulted in 33% reduction of malonyl CoA levels in livers of treated animals in relative to the vehicle.
Had a statistically nonsignificant decrease in malonyl CoA levels in skeletal muscle of rats treated with A-769662.
Animal Model: 6- to 7-weeks-old ob/ob and lean littermate mice
Dosage: 3 or 30 mg/kg b.i.d. for 5 days; 3, 10, or 30 mg/kg b.i.d. for 14 days
Administration: Intraperitoneal injection (i.p.)
Result: Significantly decreases fed plasma glucose (30-40% reduction) at 30 mg/kg in both 5 d and 14 d studies.
Reduced 42% of the fed glucose levels (16 h postdose) in the 5 day study.
Resulted in a modest reduction in body weight gain in ob/ob mice treated with 30 mg/kg dose for 5 days.
Resulted in a transient reduction in food intake in the 14 d study.
Increased the compound concentrations in liver 1 h after 30 or 3 mg/kg of A-769662 approximately 30-fold or 2.5-fold above the cellular IC50 for fatty acid synthesis.
Animal Model: Healthy male Sprague-Dawley rats (250-270 g) fed on standard diet and water ad libitum then induced diabetes with Streptozotocin (MS-Q80520) (55 mg/kg, i.p.)
Dosage: 15 or 30 mg/kg for 14 days
Administration: Intraperitoneal injection (i.p.)
Result: Attenuated the pain hypersensitivity and resulted in improved tail flick latencies and paw withdrawal threshold.
Resulted in marked reduction in motor/sensory nerve conduction velocities (MNCV and SNCV) as well as restoring impaired nerve blood flow (NBF).
Significantly reduced TUNEL-positive cells, inhibited the lipid peroxidation and improved the antioxidant defence by improving glutathione levels in the sciatic nerves of treated diabetes rats.
Significantly reduces the expression of IL-6 and TNF-α and reduced the expression of NF-κB and COX-2 compared to diabetic rats.
Reversed AMPK inactivation and associated mitochondrial biogenesis and autophagy deficits in diabetic rats.
Significantly elevated mitochondrial ATP production in treated rats.
性状 固体
颜色 Off-white to yellow

化学信息

分子量 360.39
分子式 C20H12N2O3S
CAS No. 844499-71-4

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4.50 mg/mL (12.49 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (138.74 mM; 超声助溶 (<80°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.7748 mL13.8739 mL27.7477 mL69.3693 mL
5 mM0.5550 mL2.7748 mL5.5495 mL13.8739 mL
10 mM0.2775 mL1.3874 mL2.7748 mL6.9369 mL
15 mM0.1850 mL0.9249 mL1.8498 mL4.6246 mL
20 mM0.1387 mL0.6937 mL1.3874 mL3.4685 mL
25 mM0.1110 mL0.5550 mL1.1099 mL2.7748 mL
30 mM0.0925 mL0.4625 mL0.9249 mL2.3123 mL
40 mM0.0694 mL0.3468 mL0.6937 mL1.7342 mL
50 mM0.0555 mL0.2775 mL0.5550 mL1.3874 mL
60 mM0.0462 mL0.2312 mL0.4625 mL1.1562 mL
80 mM0.0347 mL0.1734 mL0.3468 mL0.8671 mL
100 mM0.0277 mL0.1387 mL0.2775 mL0.6937 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础